Liposomes co-modified with cholesterol anchored cleavable PEG and octaarginines for tumor targeted drug delivery

Journal of Drug Targeting

Volumn 22, Issue 4, 2014, Pages 313-326

  Tang, Jie ^a   Fu, Han ^a   Kuang, Qifang ^a   Zhang, Li ^a   Zhang, Qianyu ^a   Liu, Yayuan ^a   Ran, Rui ^a   Gao, Huile ^a   Zhang, Zhirong ^a   He, Qin ^a,b  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b School of Pharmacy   (China)

Author keywords

Cholesterol; Cleavable PEG; Liposomal modification; Octaarginines; Tumor targeting

Indexed keywords

ARGININE; CHOLESTEROL; CLATHRIN; CLEAVABLE POLYETHYLENE GLYCOL; DOXORUBICIN; LIPOSOME; MACROGOL; OCTAARGININE DERIVATIVE; POLYETHYLENE GLYCOL OCTAARGININE COMODIFIED LIPOSOME; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; DRUG CARRIER; MACROGOL DERIVATIVE; OCTAARGININE; OLIGOPEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOACCUMULATION; BIOCOMPATIBILITY; CHEMICAL MODIFICATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RELEASE; DRUG TARGETING; ENDOCYTOSIS; ENDOSOME; HEMOLYSIS; MOUSE; NONHUMAN; PINOCYTOSIS; PRIORITY JOURNAL; PRODUCTIVITY; SURFACE PROPERTY; SYNTHESIS; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; ERYTHROCYTE; METABOLISM; NEOPLASMS, EXPERIMENTAL; PARTICLE SIZE; PATHOLOGY; RABBIT; TISSUE DISTRIBUTION; TOXICITY; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; CHOLESTEROL; DOXORUBICIN; DRUG CARRIERS; ERYTHROCYTES; HEMOLYSIS; LIPOSOMES; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; OLIGOPEPTIDES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; RABBITS; SURFACE PROPERTIES; TISSUE DISTRIBUTION;

EID: 84898462776     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2013.875029     Document Type: Article

References (48)

1. Lammers T, Hennink W, Storm G. Tumour-targeted nanomedi-cines: principles and practice. Br J Cancer 2008;99:392-7.
2. Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol Res 2010;62:90-9.
3. Zhao XB, Muthusamy N, Byrd JC, Lee RJ. Cholesterol as a bilayer anchor for PEGylation and targeting ligand in folate-receptor-targeted liposomes. J Pharm Sci 2007;96:2424-35.
4. Dadashzadeh S, Mirahmadi N, Babaei MH, Vali AM. Peritoneal retention of liposomes: effects of lipid composition, PEG coating and liposome charge. J Control Release 2010;148:177-86.
5. Gabizon A, Price DC, Huberty J, et al. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. Cancer Res 1990;50:6371-8.
6. Mileykovskaya E, Fishov I, Fu X, et al. Effects of phospholipid composition on MinD-membrane interactions in vitro and in vivo. J Biol Chem 2003;278:22193-8.
7. Ruenraroengsak P, Cook JM, Florence AT. Nanosystem drug targeting: facing up to complex realities. J Control Release 2010; 141:265-76.
8. Choi JS, MacKay JA, Szoka FC. Low-pH-sensitive PEG-stabilized plasmid-lipid nanoparticles: preparation and characterization. Bioconjug Chem 2003;14:420-9.
9. Mok H, Bae KH, Ahn CH, Park TG. PEGylated and MMP-2 specifically dePEGylated quantum dots: comparative evaluation of cellular uptake. Langmuir 2009;25:1645-50.
10. Sun P, Zhou D, Gan Z. Novel reduction-sensitive micelles for triggered intracellular drug release. J Control Release 2011;155: 96-103.
11. Xu H, Deng Y, Chen D, et al. Esterase-catalyzed dePEGylation of pH-sensitive vesicles modified with cleavable PEG-lipid derivatives. J Control Release 2008;130:238-45.
12. Maxwell DM, Lenz DE, Groff WA, et al. The effect of carboxylesterase inhibition on interspecies differences in soman toxicity. Toxicol Appl Pharmacol 1987;88:66-76.
13. Kuai R, Yuan W, Qin Y, et al. Efficient delivery of payload into tumor cells in a controlled manner by TAT and thiolytic cleavable PEG co-modified liposomes. Mol Pharm 2010;7:1816-26.
14. McNeeley KM, Karathanasis E, Annapragada AV, Bellamkonda RV. Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors. Biomaterials 2009;30:3986-95.
15. Torchilin V. Membrane barriers for bringing drugs inside cells and inside cell organelles. J Membra Sci Technol. 2013;3:e114. doi: 10.4172/2155-9589. 1000e114.
16. Futaki S, Hirose H, Nakase I. Arginine-rich peptides: methods of translocation through biological membranes. Curr Pharm Des 2013; 19:2863-8.
17. Futaki S, Suzuki T, Ohashi W, et al. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 2001;276:5836-40.
18. Khalil IA, Kogure K, Futaki S, Harashima H. Octaarginine-modified liposomes: enhanced cellular uptake and controlled intracellular trafficking. Int J Pharm 2008;354:39-48.
19. Wender PA, Galliher WC, Goun EA, et al. The design of guanidinium-rich transporters and their internalization mechanisms. Adv Drug Deliv Rev 2008;60:452-72.
20. Maeda T, Fujimoto K. A reduction-triggered delivery by a liposomal carrier possessing membrane-permeable ligands and a detachable coating. Coll Surf B Biointerfaces 2006;49:15-21.
21. Sharma G, Modgil A, Layek B, et al. Cell penetrating peptide tethered bi-ligand liposomes for delivery to brain in vivo: biodistribution and transfection. J Control Release 2013;167:1-10.
22. Koren E, Torchilin V. Cell-penetrating peptides: breaking through to the other side. Trends Mol Med 2012;18:385-93.
23. Koshkaryev A, Sawant R, Deshpande M, Torchilin V. Immunoconjugates and long circulating systems: origins, current state of the art and future directions. Adv Drug Deliv Rev 2013;65: 24-35.
24. Sawant RM, Hurley JP, Salmaso S, et al. "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocar-riers. Bioconjugate Chem 2006;17:943-9.
25. Tang J, Zhang L, Liu Y, et al. Synergistic targeted delivery of payload into tumor cells by dual-ligand liposomes modified with transferrin and TAT. Int J Pharm 2013;454:31-40.
26. Yin Y, Wu X, Yang Z, et al. The potential efficacy of R8-modified paclitaxel-loaded liposomes on pulmonary arterial hypertension. Pharm Res 2013;30:2050-62.
27. Qin Y, Chen H, Yuan W, et al. Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery. Int J Pharm 2011;419:85-95.
28. Ogawara K, Un K, Minato K, et al. Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: importance of vascular permeability within tumors. Int J Pharm 2008;359: 234-40.
29. Nie Y, Duan Y, Zhang Z. Evaluation of blood compatibility of surface modification treated poly (D, L-lactic and gly-colic acid) with mPEG block copolymer. J Biomed Eng 2007;24: 336-9.
30. Xiong XB, Huang Y, Lu WL, et al. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release 2005;107:262-75.
31. Kibria G, Hatakeyama H, Ohga N, et al. Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. J Control Release 2011;153:141-8.
32. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
33. Abu Lila AS, Doi Y, Nakamura K, et al. Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor. J Control Release 2010;142:167-73.
34. Zhang C, Liu T, Su Y, et al. A near-infrared fluorescent heptamethine indocyanine dye with preferential tumor accumulation for in vivo imaging. Biomaterials 2010;31:6612-17.
35. Qi XR, Maitani Y, Nagai T. Effect of soybean-derived sterols on the in vitro stability and the blood circulation of liposomes in mice. Int J Pharm 1995;114:33-41.
36. Kuai R, Yuan W, Li W, et al. Targeted delivery of cargoes into a murine solid tumor by a cell-penetrating peptide and cleavable poly(ethylene glycol) comodified liposomal delivery system via systemic administration. Mol Pharm 2011;8: 2151-61.
37. Ogawara K, Un K, Tanaka K, et al. Higaki In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: involvement of cytotoxic effect on vascular endothelial cells. J Control Release 2009;133:4-10.
38. Cole AJ, David AE, Wang J, et al. Magnetic brain tumor targeting and biodistribution of long-circulating PEG-modified, cross-linked starch-coated iron oxide nanoparticles. Biomaterials 2011;32: 6291-301.
39. Mudhakir D, Akita H, Harashima H. Topology of octaarginines (R8) or IRQ ligand on liposomes affects the contribution of macropinocytosis-and caveolae-mediated cellular uptake. React Funct Polym 2011;71:340-3.
40. Kale AA, Torchilin V. 'Smart' drug carriers: PEGylated TATp-modified pH-sensitive liposomes. J Liposome Res 2007;17: 197-203.
41. Garbuzenko O, Barenholz Y, Priev A. Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer. Chem Phys Lipids 2005;135:117-29.
42. Kenworthy AK, Hristova K, Needham D, McIntosh TJ. Range and magnitude of the steric pressure between bilayers containing phospholipids with covalently attached poly(ethylene glycol). Biophys J 1995;68:1921-36.
43. Li SD, Huang L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim Biophys Acta 2009; 1788:2259-66.
44. Koren E, Apte A, Jani A, Torchilin V. Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity. J Control Release 2012;160:264-73.
45. Hussain S, Pluckthun A, Allen TM, Zangemeister Wittke U. Antitumor activity of an epithelial cell adhesion molecule-targeted nanovesicular drug delivery system. Mol Cancer Ther 2007;6: 3019-27.
46. Mauk MR, Gamble RC, Baldeschwieler JD. Targeting of lipid vesicles: specificity of carbohydrate receptor analogues for leukocytes in mice. PNAS 1980;77:4430-4.
47. Bae YH. Drug targeting and tumor heterogeneity. J Control Release 2009;133:2-3.
48. Greller LD, Tobin FL, Poste G. Tumor heterogeneity and progression: conceptual foundations for modeling. Invasion Metastasis 1996;16:177-208.